Clinical trial NCT03291080: Oral Liquid 13-cis-retinoic Acid (13-CRA)
Official title: Relative Bioavailability and Comparative Pharmacokinetics of 13-CRA Oral Liquid and Extracted Capsule Formulations: a Randomised, Open Label, Multi-dose, Cross-over Clinical Trial in Patients Requiring Treatment Cycles of 13-CRA.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Neuroblastoma
Lead sponsor: Nova Laboratories Limited
Sponsor class: INDUSTRY
First posted: 2017-09-25
Enrollment: 20
Sex: ALL
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: An open label, randomised, multiple dose, cross-over relative bioavailability and pharmacokinetics trial of a novel oral liquid and capsule formulations of 13-CRA administered to patients from 0 months - \< 21 years.

Detailed description: All patients requiring at least two cycles of 13-CRA therapy will be eligible for recruitment into the trial.

13-CRA will be prescribed to patients according to local treatment protocols at each clinical site. The dose administered will be 200mg/m2/day for both test and reference product. Patients with a body weight of ≤12kg will receive a dose of 160 mg/m2/day.

The pharmacokinetics of 13-CRA liquid (test product) and extracted from capsule (reference product) will be evaluated over two months. Prior to the initiation of 13-CRA treatment as part of the trial, patients will be randomised to receive either liquid or capsule formulation in "My-CRA month 1". The patients will then cross-over to the alternative formulation in "My-CRA month 2". The patients on the trial who require further treatment will revert to standard therapy i.e. 13-CRA extracted from capsules according to local practice.

Eligibility criteria: Inclusion Criteria:

1. Male or female aged from 0 years to \< 21 years of age.
2. Patient with high risk neuroblastoma, or unresectable, unfavourable histology intermediate risk neuroblastoma the latter age ≥ 18 months at diagnosis
3. Patient who is scheduled to receive at least two treatment cycles of 13-CRA.
4. Patient who cannot swallow 13-CRA capsules (i.e. requires extraction of 13-CRA from the capsules).
5. Negative pregnancy test for females of child-bearing potential before initiation of treatment, and sexually active patients and partners agreeing to undertake adequate contraceptive measures (see section 4.5).
6. Provision of a single or double lumen central venous catheter for sampling (i.e. already in place).
7. Parent(s)/legal guardian able and willing to provide written informed consent for the patient to take part in the trial.
8. Where applicable, the patient should assent to undergo blood sampling for pharmacokinetic purposes and to allow physiological measurements to be made.

Exclusion Criteria:

1. Any clinically significant medical condition or abnormality, which, in the opinion of the investigator, might compromise the safety of the patient or which might interfere with the trial.
2. Diagnosis of high-risk neuroblastoma (HRNBL) which is currently being treated on the SIOPEN HRNBL trial (patients who have exited this trial will be eligible).
3. Known allergy to 13-CRA or any of the excipients.
4. Inadequate contraception measures in females of childbearing age.
5. Receiving concomitant treatment with tetracyclines.

Prior to each cycle:

1. Total bilirubin ≤ 1.5 x normal, and (SGPT) ALT ≤ 5 x normal. Veno-occlusive disease if present, should be stable or improving.
2. Skin toxicity no greater than CTCAE Grade 1(10)
3. Serum triglycerides \<5.65mmol/L.
4. No haematuria and / or proteinuria on urinalysis.
5. Serum calcium ≤ 2.9mmol/L.
6. Serum creatinine based on age / gender as follows:

   Age Maximum Serum Creatinine µmol/L Male Female 1 month to \< 6 months 35 35 6 months to \< 1 year 44 44 1 to \< 2 years 53 53 2 to \< 6 years 70 70 6 to \< 10 years 88 88 10 to \< 13 years 106 106 13 to \< 16 years 132 124

   ≥ 16 years 150 124
7. Patients with a seizure disorder must be well controlled and taking anticonvulsants. CNS toxicity \< grade 2 (CTCAE).

Withdrawal Criteria:

1. Positive pregnancy test - pregnancy testing will be undertaken before treatment commences and routinely before each course of treatment in females of childbearing potential. If a patient is found to be pregnant during the trial, the next course of treatment will not be given until the pregnancy has been discussed with the treating clinician, and the patient will be withdrawn from the trial whether or not treatment is continued.
2. Request of the patient, for any reason.
3. Discretion of the investigator.

Primary outcomes:
measure: Relative Bioavailability
timeFrame: On day 1 and 14 of treatment
Secondary outcomes:
measure: Maximum Plasma Concentration (Cmax)
timeFrame: On day 1 and 14 of treatment
measure: Time to Maximum Concentration (Tmax)
timeFrame: On day 1 and 14 of treatment
measure: Area Under Plasma Concentration Time Curve (AUC) Metabolite
timeFrame: On day 1 and 14 of treatment
measure: Cmax (ng/mL)- Metabolite
timeFrame: On day 1 and 14 of treatment
measure: T Max of Metabolite
timeFrame: On day 1 and 14 of treatment
Other outcomes:
Locations:
city: Birmingham
country: United Kingdom
facility: Bruce Morland
city: Bristol
country: United Kingdom
facility: Dr Antony Ng
city: Cambridge
country: United Kingdom
facility: Dr Amos Burke
city: Edinburgh
country: United Kingdom
facility: Mark Brougham
city: Leeds
country: United Kingdom
facility: Dr Martin Elliott
city: London
country: United Kingdom
facility: Dr Guiseppe Barone
city: Manchester
country: United Kingdom
facility: Dr Guy Makin
city: Nottingham
country: United Kingdom
facility: Dr Madhumita Dandapani
city: Oxford
country: United Kingdom
facility: Kate Wheeler
city: Sutton
country: United Kingdom
facility: Sucheta Vaidya
Study officials:
affiliation: Nova Laboratories Limited
name: Hussain Mulla, PhD
role: STUDY_DIRECTOR
References:
citation: Veal GJ, Tweddle DA, Visser J, Errington J, Buck H, Marange J, Moss J, Joseph S, Mulla H. Pharmacokinetics and Safety of a Novel Oral Liquid Formulation of 13-cis Retinoic Acid in Children with Neuroblastoma: A Randomized Crossover Clinical Trial. Cancers (Basel). 2021 Apr 14;13(8):1868. doi: 10.3390/cancers13081868.